Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Thyroid Neoplasms × Epinephrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pain, Postoperative 3 Breast Neoplasms 3 Stomach Neoplasms 2 Pain 2 Uterine Cervical Neoplasms 1 Uterine Cervical Dysplasia 1 Thyroid Neoplasms 1 Supratentorial Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Rectal Neoplasms 1 Postoperative Hemorrhage 1 Polyposis, Gastric 1 Oropharyngeal Neoplasms 1 Nerve Block 1 Neoplasm, Residual 1 Myelodysplastic Syndromes 1 Musculoskeletal Diseases 1 Multiple Myeloma 1 Mouth Neoplasms 1 Malignant Neoplasms of Male Genital Organs 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Follicular 1 Lymphoma 1 Lung Neoplasms 1 Leukemia, Hairy Cell 1 Leukemia 1 Leiomyoma 1 Hypotension 1 Hodgkin Disease 1 Head and Neck Neoplasms 1

Interventions

Iodine-131 14 lenvatinib 11 Magnetic Resonance Spectroscopy 10 trametinib 9 Thyrotropin Alfa 9 Sorafenib 9 vandetanib 8 pembrolizumab 8 Paclitaxel 8 dabrafenib 7 Thyroxine 7 selpercatinib 6 Surgical Procedures, Operative 6 Sunitinib 6 Everolimus 6 pazopanib 5 cabozantinib 5 Vemurafenib 5 Saline Solution 5 Cyclophosphamide 5 anlotinib 4 Triiodothyronine 4 Thyroidectomy 4 Radiofrequency Ablation 4 Nivolumab 4 Fluorodeoxyglucose F18 4 Docetaxel 4 Dexmedetomidine 4 fosbretabulin 3 durvalumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02112370 2017-08-04

REBT

Seoul National University Hospital

Phase 3 Completed

148 enrolled 17 charts

Goiter, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡